pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,449 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1554Endpoints1217BioSpace556Fierce Biotech553BioPharma Dive464raps192onclive165fda recalls
therapy area
allOncology10356Rare Disease2700Immunology2439Cardiology2280Hematology1880Pulmonology1870Vaccines
  • Proposed US Census rule changes could distort health data, warns epidemiologist
    Nancy Krieger, a professor of social epidemiology at Harvard T.H. Chan School of Public Health, wrote an opinion piece warning that proposed changes to the U.S. decennial census could have severe p…
    STAT · 11d agoRegulatoryNegative↗ source
  • FDA week: HHS launches vaccine injury study, midterms may reshape oversight committees, and patent thickets threaten generics
    The Department of Health and Human Services announced a new agency‑wide effort to examine and address injuries that may be linked to vaccines. The initiative will coordinate research across FDA and…
    raps · 11d agoRegulatoryNeutral↗ source
← prev
page 8 of 98
next →
102
fda medwatch93
globenewswire health73
fda press54
1617
Psychiatry & CNS1106
Ophthalmology844
Endocrinology & Metabolism686
Pain654
Nephrology634
  • Study finds rising patent thickets may slow generic drug competition
    A recent special communication in JAMA reports that the number of patents linked to FDA‑approved small‑molecule drugs has risen over the past 15 years. The increase is driven largely by non‑primary…
    raps · 11d agoNeutral↗ source
  • Humana tops 2027 Medicare Advantage star ratings as insurers face $13 billion in bonus payouts and legal challenges
    The Centers for Medicare & Medicaid Services released the 2027 star ratings for Medicare Advantage plans, with Humana emerging as the top‑scoring insurer. Plans that achieve at least four out of f…
    STAT · 11d agoRegulatoryNeutral↗ source
  • FDA issues early alert on Philips Lumify ultrasound system software and connection problems
    The FDA’s Center for Devices and Radiological Health has released an Early Alert about a potential high‑risk issue with Philips Lumify diagnostic ultrasound devices. The problem involves either a s…
    fda medwatch · 11d agoRegulatoryNegative↗ source
  • Biotech executive Steven Quay dropped from consideration for NIAID director role
    Steven Quay, a biotech executive known for promoting the lab‑leak theory, was reportedly in the running to lead the National Institute for Allergy and Infectious Diseases. A source familiar with t…
    STAT · 11d agoNeutral↗ source
  • Life Biosciences injects experimental cellular reprogramming drug into three glaucoma patients, reports no serious adverse events
    Life Biosciences provided an update on its early‑stage glaucoma study involving its experimental cellular reprogramming therapy. The company said three patients have each received a single intravi…
    STAT · 11d agoPositive readoutPositive↗ source
  • Researcher uses Reddit data to map post-Roe abortion access barriers
    Betsy Pleasants, a postdoctoral researcher at the Center for Women’s Health Research, began studying how the Covid‑19 pandemic affected abortion services while a graduate student at UC Berkeley. W…
    STAT · 11d agoNeutral↗ source
  • Q32 Bio appoints José Trevejo as chief medical officer, coming from Enveda Therapeutics
    STAT+ ran its regular "up and down the ladder" column highlighting recent personnel moves in the pharma sector. The feature invites readers to share hiring, promotion and departure news for broader…
    STAT · 11d agoNeutral↗ source
  • MAHA movement fades as midterms approach, lacking visibility and funding
    Health secretary Robert F. Kennedy Jr.'s Make America Healthy Again (MAHA) movement entered the political arena promising to rally an unlikely coalition of activists and deliver significant gains f…
    STAT · 11d agoNegative↗ source
  • Roche partners with Chinese biotech Defand Therapeutics to co-develop new medicines
    Roche announced a partnership with Chinese biotech startup Defand Therapeutics aimed at joint discovery of new drug candidates. Unlike the typical licensing deals where companies obtain rights to…
    STAT · 12d agoDealPositive↗ source
  • Argenx halts late-stage Vyvgart trial in Sjogren’s disease after futility finding, shares tumble 13%
    Argenx announced it is ending the Phase 3 UNITY trial of its Vyvgart Hytrulo injection in Sjogren’s disease after an independent data monitoring committee concluded the study would not meet its pri…
    BioSpace · 12d agoNegative readoutNegative↗ source
  • Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trial
    Argenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…
    STAT · 12d agoNegative readoutNegative↗ source
  • Newron reports five deaths in schizophrenia trial as FDA keeps hold on evenamide study
    Newron Pharmaceuticals disclosed that five participants have died in its late-stage schizophrenia trial, with four deaths among those receiving the investigational drug evenamide and one death amon…
    BioSpace · 12d agoRegulatoryNegative↗ source
  • Zealand Pharma’s petrelintide shows 9% weight loss in Phase 2 but fails to improve blood sugar, analysts unimpressed
    Zealand Pharma, in partnership with Roche, reported results from the Phase 2 ZUPREME-2 trial of petrelintide, a long‑acting human amylin analog, in 220 obese or overweight patients with type 2 diab…
    BioSpace · 12d agoNegative readoutNeutral↗ source
  • Matchpoint Therapeutics raises $150 million Series B to move oral T-cell modulator MPT-062 toward clinical trials
    Matchpoint Therapeutics announced the closing of a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures and several exi…
    BioSpace · 12d agoDealPositive↗ source
  • Roche partners with China's Defand Therapeutics to discover molecular glue medicines
    Roche announced a collaboration with Chinese biotech Defand Therapeutics aimed at discovering new molecular glue medicines for oncology and immune‑mediated diseases. Unlike typical licensing deals…
    STAT · 12d agoDealPositive↗ source
  • CMS proposes changes to curb 340B drug discount program’s costly subsidies to safety-net hospitals
    Casey B. Mulligan, chief economist and chief regulatory officer at HHS, wrote an opinion piece outlining a major flaw in the 340B drug discount program. The program, created in 1992, gives steep di…
    STAT · 12d agoRegulatoryNegative↗ source
  • ARM playbook proposes data reuse to slash gene-editing R&D costs and broaden rare-disease therapies
    The Alliance for Regenerative Medicine released a new playbook that outlines how developers of gene‑editing therapies can reuse existing data to lower research and development expenses. The guidanc…
    BioSpace · 12d agoRegulatoryPositive↗ source
  • NIH funding uncertainty clouds US research, dampens biotech investor sentiment
    The latest episode of STAT’s “The Readout LOUD” podcast examined how the National Institutes of Health is allocating its budget and the growing uncertainty surrounding future funding. Hosts Elaine…
    STAT · 12d agoNegative↗ source
  • FDA extends safety review of mifepristone into next year, report due by March 2027
    The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year. The agency expects to finish the saf…
    STAT · 12d agoRegulatoryNeutral↗ source
  • Venture debt becomes central financing option for late-stage European biotech
    BioSpace’s Denatured podcast recently featured Jennifer McMahon of Seroba and Joey Mason of Claret Capital discussing the growing role of venture debt in European biotech. The guests explained tha…
    BioSpace · 12d agoPositive↗ source
  • Tailored breast cancer care for older women gains momentum as researchers highlight age-specific tumor differences
    Older women represent a large share of breast cancer diagnoses, with nearly half of cases occurring in patients 65 or older and about one-fifth in those 75 and older. Despite these numbers, clinic…
    STAT · 12d agoPositive↗ source
  • Everlywell launches AI tool to predict breast cancer risk directly to consumers
    Everlywell, a digital health company known for offering at-home lab tests, has introduced a new artificial intelligence algorithm that evaluates breast cancer risk from medical images. The company…
    STAT · 12d agoPositive↗ source
  • Experts say U.S. must step up to match Europe’s progress in eliminating hepatitis C
    The authors argue that England and several other nations are nearing hepatitis C elimination, while the United States lags behind. They point to recent public attention, such as Pamela Anderson’s…
    STAT · 12d agoNeutral↗ source